Genomic insights into adverse drug reactions

Carbamazepine (CBZ) is a drug frequently used as an anticonvulsant and mood stabilizer in the treatment of epilepsy and bipolar disorder. Cutaneous adverse drug reactions (cADRs) characterized by acute inflammatory reactions in skin and mucous membranes are dose-independent, unpredictable and sometimes life-threatening. Manifestations range from a mild erythematous maculopapular rash to a progressive, fulminating, severe variant with extensive mucocutaneous epithelial necrosis, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug-induced hypersensitivity syndrome (DIHS), which is also referred to as drug rash with eosinophilia and systemic symptoms (DRESS).

Almost all available drugs have been reported to have a risk of causing a cADR, and some drugs, such as CBZ, allopurinol, abacavir and nevirapine, are known to cause a very high incidence of severe cADRs, including SJS and TEN [1]. It has been proposed recently that binding of drugs and/or their metabolites to human leukocyte antigen (HLA) may trigger undesirable immune responses. When the antigen is presented on HLA class II molecules, CD4+ helper T cells are activated. If the antigen is presented on class I molecules, it is likely to activate CD8+ cytotoxic T cells. Although the detailed mechanisms have not been clarified, HLA molecules are considered to be critical in the pathogenesis of severe cADRs. Therefore, genetic association analyses between HLA alleles and cADRs have been performed by many research groups, and several HLA alleles have been identified as major susceptibility factors that predispose an individual to develop cADRs. The first report demonstrating the critical involvement of a specific HLA allele in development of severe cADRs was published in 2002 [2]. This discovery had a big impact and resulted in alterations to the labeling of drugs. The report described a study of 18 Caucasian HIV patients with abacavir-induced hypersensitivity syndrome (HSS), and it revealed that the frequency of HLA-B*5701 in these patients was significantly higher compared with the abacavir-tolerant control subjects (78% versus 2%; odds ratio, 117). Based on the subsequent large prospective clinical trial in 2008 [3], the US Food and Drug Administration (FDA) updated the label of abacavir to recommend that all patients should be screened for HLA-B*5701 before initiation of treatment.

New insights into carbamazepine reactions and HLA

Two studies published recently in the New England Journal of Medicine should facilitate the development of genetic tests to predict high-risk individuals for potentially life-threatening adverse reactions caused by CBZ [4,5]. Previously, a group in Taiwan reported that the HLA-B*1502 allele was associated with SJS-TEN induced by CBZ in Han Chinese patients (Table 1) [6,7]. Based on these results, in 2007 the US FDA recommended genotyping all patients with ancestry in populations in which HLA-B*1502 may be present. The recent prospective clinical trial, published in the New England Journal of Medicine, led by the same Taiwanese group, demonstrated that SJS-TEN did not develop in any of the HLA-B*1502-negative patients receiving CBZ (n = 4,120), indicating that the HLA-B*1502 screening should reduce the incidence of life-threatening adverse reactions caused by CBZ [4]. However, allelic frequencies of the HLA loci differ significantly among different ethnic populations.
groups. For example, the HLA-B*1502 allele is present at high frequencies in Southeast Asians, such as the Han Chinese in Taiwan (5.9%) and people from Thailand (8.5%), but it is less than 0.1% in Japanese and Caucasian populations [8], although the incidence of CBZ-induced cADRs is also relatively high in these populations. Thus, HLA-B*1502 is unlikely to be a good genetic predictor for the CBZ-induced cADRs in Japanese and Caucasian populations.

The second study was a multicenter study led by teams from the UK and Ireland, and it used a genome-wide association study (GWAS) approach. The study showed that the HLA-A*3101 allele was associated with CBZ-induced cADRs, including SJS-TEN [5]. It demonstrated that a SNP showing a significant association had previously been shown to be a proxy for the HLA-A*3101 allele in subjects of European descent. The subsequent HLA analysis revealed that HLA-A*3101 was a risk factor for the HSS (odds ratio, 12.41), maculopapular exanthema (MPE; odds ratio, 8.33) and SJS-TEN (odds ratio, 25.93), suggesting that the HLA-A*3101 allele is an important predictor of the ‘full spectrum’ of CBZ-induced cADRs (Table 1). The authors concluded that it may be possible to reduce the incidence of CBZ-induced cADRs from 5% to 3.8% by using genetic diagnosis to exclude patients with the HLA-A*3101 allele from CBZ treatment.

**Implications for future research and treatment**

Previously, and also using a GWAS, we reported that HLA-A*3101 allele was a genetic risk factor for the full spectrum of CBZ-induced cADRs, including SJS-TEN and DIHS/DRESS, in a Japanese population (Table 1) [9]. In addition, this allele has been shown to be associated with CBZ-induced MPE in subjects of Han Chinese ancestry (Table 1) [7]. HLA-A belongs to the HLA class I heavy chain paralogs that play a central role in the immune system by presenting peptides derived from the endoplasmic reticulum lumen. It is considered that the association of the HLA allele with CBZ-induced cADRs should reflect variations in antigen-binding affinities of HLA-A that might affect the immune response in the pathogenesis of the cADRs. Patients will greatly benefit from HLA-A*3101 genotyping to predict the risk of CBZ-induced cADRs because there are several alternative drugs to CBZ for treatment of epilepsy; these drugs include valproic acid, gabapentin, levetiracetam, and topiramate, which induce cADRs with lower prevalence compared with CBZ. Although the efficacy of these alternative drugs might be inferior to CBZ for treating epilepsy, the prevention of CBZ-induced cADRs, which are sometimes life-threatening, is more important for patients. Thus, these findings should provide useful information for improving the personalized CBZ treatment of epilepsy.

Interestingly, the Taiwanese study revealed that MPE and HSS did not show a significant association with HLA-B*1502 (with only one positive subject out of thirty-one patients), while the HLA-A*3101 allele was observed in only one of sixty patients with SJS-TEN [7], suggesting that the pathogenesis might be different between SJS-TEN and other cADRs, such as MPE. However, the full spectrum of CBZ-induced cADRs, including SJS-TEN, was associated with the HLA-A*3101 allele in Japanese

---

**Table 1. HLA alleles associated with carbamazepine-induced cutaneous adverse drug reactions**

| Population         | Target allele | Type of cADR | Selectivity in cases* | Odds ratio | Reference     |
|--------------------|---------------|--------------|-----------------------|------------|---------------|
| Han Chinese in Taiwan | HLA-B*1502  | SJS-TEN      | 59/60                 | 1,357      | [7]           |
|                    |               | HSS          | 0/13                  | –          | [7]           |
|                    |               | MPE          | 1/18                  | –          | [7]           |
|                    | HLA-A*3101    | SJS-TEN      | 1/60                  | –          | [7]           |
|                    |               | HSS          | 2/13                  | –          | [7]           |
|                    |               | MPE          | 6/18                  | 17.5       | [7]           |
| Japanese           | HLA-A*3101    | SJS-TEN      | 5/6                   | 33.9       | [9]           |
|                    |               | DIHS         | 21/36                 | 9.5        | [9]           |
|                    |               | Other        | 19/35                 | 8.0        | [9]           |
| European           | HLA-A*3101    | SJS-TEN      | 5/12                  | 25.93      | [5]           |
|                    |               | HSS          | 10/27                 | 12.41      | [5]           |
|                    |               | MPE          | 23/106                | 8.33       | [5]           |
| Thai               | HLA-B*1502    | SJS-TEN      | 37/42                 | 54.76      | [10]          |
| Malaysian          | HLA-B*1502    | SJS-TEN      | 12/16                 | 16.15      | [11]          |

*Number of patients with the target allele/number of patients with type of cADR. cADR, cutaneous adverse drug reaction; DIHS, drug-induced hypersensitivity syndrome; HLA, human leukocyte antigen; HSS, hypersensitivity syndrome; MPE, maculopapular exanthema; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis.
and European populations. Both HLA-A and HLA-B belong to major histocompatibility complex I molecules. Thus, there may be common underlying mechanisms involved in the CBZ-induced cADRs, although HLA-B*1502 appears to be specifically involved in CBZ-induced SJS-TEN. The discrepancy in the results of association of HLA-A*3101 with SJS-TEN between Japanese/European and Taiwanese studies might be due to ethnic differences in allele frequencies of HLA-B*1502. It has been found that the HLA-B*1502 allele is extremely rare in Japanese and Caucasians, and this might have a larger effect size on the risk of SJS-TEN than that of HLA-A*3101.

Although the impact of the association of HLA-A*3101 with CBZ-induced cADRs is not as high as that of HLA-B*1502, improved labeling of CBZ to recommend the avoidance of CBZ in patients with HLA-A*3101 should benefit individuals at risk. However, a global network for the collection of data on patients with cADRs is required to show the usefulness of HLA testing for epilepsy treatments. In addition, the clarification of the molecular mechanisms underlying the associations of HLA-B*1502 and HLA-A*3101 with the risk of CBZ-induced cADRs would encourage the development of new technology, which may also be useful for the screening of compounds for toxicity earlier in the drug discovery process.

Abbreviations
cADR, cutaneous adverse drug reactions; CBZ, carbamazepine; DIHS, drug-induced hypersensitivity syndrome; DRESS, drug rash with eosinophilia and systemic symptoms; FDA, Food and Drug Administration; GWAS, genome-wide association study; HLA, human leukocyte antigen; HSS, hypersensitivity syndrome; MPE, maculopapular exanthema; SJS, Stevens-Johnson syndrome; SNP, single nucleotide polymorphism; TEN, toxic epidermal necrolysis.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
Both authors participated in writing the manuscript.

Author details
Research Group for Pharmacogenomics, RIKEN Center for Genomic Medicine, Yokohama 230-0045, Japan. 1Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan

Published: 30 May 2011

References
1. Chung WH, Hung SJ, Chen YT: Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol 2007, 7:317-323.
2. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Maromorte C, Maxwell D, James I, Christiansen FT: Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002, 359:727-732.
3. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyreva O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thoburn D, Benbow A, PREDICT-1 Study Team: HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008, 359:568-579.
4. Chen P, Lin JJ, Lu CS, Ong CT, Hsieh PF, Yang CC, Tai CT, Wu SL, Lu CH, Hsu YC, Yu HY, Ro LS, Lu CT, Chu CC, Tsai JJ, Su YH, Lan SH, Sun SG, Lin SY, Chuang HR, Huang LC, Chen YJ, Tsai PJ, Liao HT, Lin YH, Chen CH, Chung WH, Hung SI, Wu JY, Chang CF, et al; Taiwan SJS Consortium: Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 2011, 364:1126-1133.
5. McCormack M, Alfrevic A, Bourgeois S, Farell JJ, Kasperavičiūtė D, Carrington M, Sills GJ, Marion T, Jia X, de Bakker PI, Chinthapalli K, Molokhia M, Johnson MR, O’Connor GD, Chaila E, Alhusaini S, Shenna KV, Radtke RA, Heinen EL, Walley N, Pandolfo M, Pichler W, Park BK, Depondt C, Sisodiya SM, Goldstein DB, Deloukas P, Delanty N, Cavallini GL, Pirmohamed M, HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011, 364:1134-1143.
6. Chung WH, Hung SI, Hong HS, Hsh MS, Yang LC, Ho HC, Wu JY, Chen YT: Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004, 428:486.
7. Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, Hu SL, Wu MT, Chen GS, Wong TW, Hsiao PF, Chen WH, Shih HY, Fang WH, Wei CY, Lou YH, Huang YL, Lin JJ, Chen YT: Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006, 16:297-306.
8. The Allele Frequency Net Database [http://www.allelefrequencies.net]
9. Ozeki T, Mushiroda T, Yowang A, Takahashi A, Kubo M, Shirakata Y, Ikezawa Z, Iijima M, Shiohara K, Kamatani N, Nakamura Y: Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 2011, 20:1034-1041.
10. Tsairaneevakul T, Tamkao S, Santarauongtong T, Chen P, Lin SY, Chen WH, Konyoung P, Khunarkornsiri U, Auvichayapat N, Pavakul K, Kulkantakorn K, Choonhakarn C, Phonjiampan S, Piyaikutak N, Aungaree T, Pongpakde S, Yodnopalgav P: Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 2010, 51:926-930.
11. Chang CC, Too CI, Murad S, Hussein SH: Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. Int J Dermatol 2011, 50:221-224.

doi:10.1186/gm243
Cite this article as: Mushiroda T, Nakamura Y: Personalizing carbamazepine therapy. Genome Medicine 2011, 3:28.